Tatsuaki Morokata, Ph.D.
President, Astellas Innovation Management LLC
Divisional Senior Vice President
Innovation & Incubation Research Labs
Drug Discovery Research
Astellas Pharma Inc.
Dr. Tatsuaki Morokata joined Astellas in 1995(formely Yamanouchi Pharmaceutical Co. Ltd.), and he currently manages Innovation & Incubation Research Labs and Astellas Innovation Management LLC which are responsible for acquiring internal and external innovation opportunities in the preclinical development stage, including strategy planning, screening, scientific, assessment and alliance negotiations.
His other professional and managerial experience at Astellas include the following: Executive Director, New Product Science Strategy Group, Product and Portfolio Strategy (2017- March 2018 ); Executive Director, ImmunoScience Research Unit, Research and Portfolio Science (2014-2016); Senior Director, Innovation Research Lab, Molecular Medicine Research Labs (2012-2013). Post Doctorial Research Fellow at Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School (2009 to 2010).
Dr. Morokata has more than 23 years of experience in immunology research from early to late stage drug discovery.
He received his Ph.D. in Pharmaceutical Science in the University of Tokyo.
Mark (Makoto) Ohori, Ph.D.
Senior Director, Head of AIM Cambridge DRY
Dr. Mark (Makoto) Ohori joined AIM as Head of AIM Cambridge DRY in April 2018. Previously he led Potenza Therapeutics' partnership with Astellas, as Co-chair of the Joint Steering Committee (JSC) and Senior Scientific Director for Asellas JSC to establish Astellas' future research capabilities and Immuno-Oncology pipeline.
Prior to that, Dr. Ohori was working at Astellas Venture Management (AVM) as an Investment Director where he led partnering deals with or investments in Potenza Therapeutics, Crescendo Biologics (UK), Bicycle Therapeutics, eFFECTOR Therapeutics, Cleave Biosciences, Verastem, Tizona Therapeutics etc; and supported exits of or deals with Mitobridge, Epizyme, Verastem, Fate Therapeutics, etc.
Prior to AVM, Dr. Ohori led Astellas' efforts to boost its biologics research as the leader of the cross-organizational start-up team. He also worked at Post-Marketing Development Research Center at Fujisawa Pharmaceuticals to maximize the value of marketed products thorough clinical research collaborations with academia partners. He has experience collaborating with academic partners such as Dana-Farber Cancer Institute, Grenoble University Hospital, Dokkyo University School of Medicine, Kyoto University Hospital, and various CROs.
Dr. Ohori has authored more than 15 peer reviewed papers and invited reviews. He received his Ph.D. in Pharmaceutical Sciences from the University of Tokyo.
Hideaki Matsuoka, Ph.D.
Senior Director, Head of AIM Menlo Park DRY
Menlo Park Office
Dr. Hideaki Matsuoka joined Fujisawa Pharmaceutical Co., Ltd. - merged with Yamanouchi to become Astellas in 2005 - in April 1999. He has more than 14 years of experience in Drug Discovery Research in the field of Immunology, Cell Biology, and served as the Principal Scientist at Astellas Research Institute of America (ARIA) from 2007 to 2010 specifically focusing on early drug discovery (target identification, Hit/Lead generation and therapeutic strategy) in organ transcription.
In October 2013, when Innovation Management (AIM) was established, he moved from Drug Discovery Research to AIM. Currently he is working as Senior Director, Head of AIM Menlo Park DRY, and leading the team who are responsible for the identification and scientific evaluation of external innovation and assets.
Prior to joining AIM, he was an Associate Investment Director of Astellas Venture Management LLC. He has an established track record for leading several partnering deals (e.g. collaboration with Proteostasis Therapeutics, Inc.) since joining AIM.
He holds a Ph.D. in Agricultural Science from Kyoto University.
Menlo Park Office
Menlo Park Office